Clinuvel Pharmaceuticals Limited UR9.F Stock
Clinuvel Pharmaceuticals Limited Price Chart
Clinuvel Pharmaceuticals Limited UR9.F Financial and Trading Overview
| Clinuvel Pharmaceuticals Limited stock price | 9.37 EUR |
| Previous Close | 11.61 EUR |
| Open | 11.55 EUR |
| Bid | 11.56 EUR x 80000 |
| Ask | 11.66 EUR x 80000 |
| Day's Range | 11.55 - 11.55 EUR |
| 52 Week Range | 9.26 - 18.56 EUR |
| Volume | 360 EUR |
| Avg. Volume | 882 EUR |
| Market Cap | 578.28M EUR |
| Beta (5Y Monthly) | 0.877011 |
| PE Ratio (TTM) | 48.125 |
| EPS (TTM) | 0.35 EUR |
| Forward Dividend & Yield | 0.03 (0.23%) |
| Ex-Dividend Date | September 6, 2022 |
| 1y Target Est | N/A |
UR9.F Valuation Measures
| Enterprise Value | 415.06M EUR |
| Trailing P/E | 48.125 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 8.157422 |
| Price/Book (mrq) | 4.1001067 |
| Enterprise Value/Revenue | 5.855 |
| Enterprise Value/EBITDA | 10.139 |
Trading Information
Clinuvel Pharmaceuticals Limited Stock Price History
| Beta (5Y Monthly) | 0.877011 |
| 52-Week Change | 18.15% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 18.56 EUR |
| 52 Week Low | 9.26 EUR |
| 50-Day Moving Average | 11.82 EUR |
| 200-Day Moving Average | 13.04 EUR |
UR9.F Share Statistics
| Avg. Volume (3 month) | 882 EUR |
| Avg. Daily Volume (10-Days) | 471 EUR |
| Shares Outstanding | 49.41M |
| Float | 37.13M |
| Short Ratio | N/A |
| % Held by Insiders | 20.55% |
| % Held by Institutions | 8.87% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0.04 |
| Trailing Annual Dividend Yield | 0.34% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.062 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | June 30, 2023 |
Profitability
| Profit Margin | 37.23% |
| Operating Margin (ttm) | 57.16% |
| Gross Margin | 89.75% |
| EBITDA Margin | 57.74% |
Management Effectiveness
| Return on Assets (ttm) | 18.35% |
| Return on Equity (ttm) | 21.42% |
Income Statement
| Revenue (ttm) | 70.89M EUR |
| Revenue Per Share (ttm) | 1.44 EUR |
| Quarterly Revenue Growth (yoy) | 19.19% |
| Gross Profit (ttm) | 56.92M EUR |
| EBITDA | 40.94M EUR |
| Net Income Avi to Common (ttm) | 26.4M EUR |
| Diluted EPS (ttm) | 0.24 |
| Quarterly Earnings Growth (yoy) | 94.00% |
Balance Sheet
| Total Cash (mrq) | 140.7M EUR |
| Total Cash Per Share (mrq) | 2.85 EUR |
| Total Debt (mrq) | 1.14M EUR |
| Total Debt/Equity (mrq) | 0.82 EUR |
| Current Ratio (mrq) | 8.798 |
| Book Value Per Share (mrq) | 2.817 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 43.57M EUR |
| Levered Free Cash Flow (ttm) | 38.71M EUR |
Profile of Clinuvel Pharmaceuticals Limited
| Country | Germany |
| State | VIC |
| City | Melbourne |
| Address | 535 Bourke Street |
| ZIP | 3000 |
| Phone | 61 3 9660 4900 |
| Website | https://www.clinuvel.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.
Q&A For Clinuvel Pharmaceuticals Limited Stock
What is a current UR9.F stock price?
Clinuvel Pharmaceuticals Limited UR9.F stock price today per share is 9.37 EUR.
How to purchase Clinuvel Pharmaceuticals Limited stock?
You can buy UR9.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Clinuvel Pharmaceuticals Limited?
The stock symbol or ticker of Clinuvel Pharmaceuticals Limited is UR9.F.
Which industry does the Clinuvel Pharmaceuticals Limited company belong to?
The Clinuvel Pharmaceuticals Limited industry is Biotechnology.
How many shares does Clinuvel Pharmaceuticals Limited have in circulation?
The max supply of Clinuvel Pharmaceuticals Limited shares is 51.08M.
What is Clinuvel Pharmaceuticals Limited Price to Earnings Ratio (PE Ratio)?
Clinuvel Pharmaceuticals Limited PE Ratio is 26.77143000 now.
What was Clinuvel Pharmaceuticals Limited earnings per share over the trailing 12 months (TTM)?
Clinuvel Pharmaceuticals Limited EPS is 0.35 EUR over the trailing 12 months.
Which sector does the Clinuvel Pharmaceuticals Limited company belong to?
The Clinuvel Pharmaceuticals Limited sector is Healthcare.